As discussed, in the absence of insulin, Akt activity is suppressed and FOXO1 is transcriptionally active. This effect results in an increase in MTP, the rate-limiting enzyme in hepatic VLDL production, Everolimus increasing VLDL secretion. In addition,
FOXO1 also results in increased transcriptional activity and hepatic secretion of ApoC-III. In the circulation, this apolipoprotein inhibits the activity of lipoprotein lipase, responsible for hydrolysis and uptake of the triglyceride component of VLDL and chylomicrons, thus prolonging the persistence of VLDL.[24] In response to feeding, FOXO1 is inactivated, shutting down both these mechanisms and preventing post-prandial hyperglycemia. In states of insulin resistance, this suppression of FOXO1 activity may fail to occur resulting in both hyperglycemia and hypertriglyceridemia.[25] Additional factors appear to be involved in the lipid effects of FOXO1 as well. Early attempts to understand the effects of FOXO on hepatic lipid metabolism involved expression of various mutated forms of FOXO1 that were felt to represent selleckchem constitutively active forms of the protein. These studies seemed to imply both positive and negative effects of FOXO on lipid production and accumulation. One model for expression of constitutively active FOXO1 using a single S-253 mutated phosphorylation site led to increased hepatic triglyceride
levels but lower levels in the circulation.[26] Another model for expression of constitutively active FOXO1 using alanine substitution at all three Akt phosphorylation sites
had normal hepatic triglyceride levels[15] but showed that increased FOXO1 activity led to suppression of a number of proteins required for lipid synthesis including sterol regulatory element binding protein (SREBP)-1c, acetyl-CoA carboxylase-α (ACC), and fatty acid synthase (FAS).[15] These data are difficult to interpret unambiguously because the mutated forms of FOXO may behave differently in unanticipated selleck compound ways. Perhaps the best systems in which to study the net effects of FOXO proteins on hepatic and serum lipid homeostasis is in liver-specific multiple FOXO knockouts. Zhang et al.[27] showed that ablation of FOXO1 caused a decrease in plasma glucose without a significant effect on lipid metabolism, but simultaneous knock out of FOXO1 and FOXO3 caused hepatic steatosis, increased hepatic lipid secretion, and increased serum triglycerides.[27] While the precise mechanism for these effects could not be determined, these authors showed a negative transcriptional effect of FOXO3 and particularly the FOXO1/FOXO3 combination on two important genes of lipid synthesis, FAS, and 3-hydroxy-3-methyl-glutaryl-CoA reductase. A similar phenomenon was also observed by Tao et al.[28] who produced a hepatic-specific knockout of the combination of FoxO1, FoxO3, and FoxO4 in mice.